Key takeaways
Pavblu (aflibercept-ayyh) and Eylea (aflibercept) are both VEGF inhibitors used to treat eye conditions related to the retina, such as wet age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic retinopathy (DR), and diabetic macular edema (DME). They work by blocking proteins that cause the growth of new, leaky blood vessels in the eye. Both medications are administered as intravitreal injections by an eye specialist. Pavblu is a biosimilar to Eylea, meaning they contain the same medication and are expected to work in a similar way. But Pavblu may be a more affordable option.Common side effects for both include eye pain, blood spots on the whites of the eye, and increased eye pressure. Both medications carry risks of serious side effects like eye infections and retinal detachment.
